OncoMatch/Clinical Trials/NCT05069857
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Is NCT05069857 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Camrelizumab (anti-PD-1 inhibitor) and Apatinib (anti-VEGFR inhibitor) for oral squamous cell carcinoma.
Treatment: Camrelizumab (anti-PD-1 inhibitor) · Apatinib (anti-VEGFR inhibitor) — To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression > 10 CPS (CPS score > 10)
The combined positive score (CPS score) of PD-L1 expression > 10
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 3,000/mm3, hemoglobin ≥ 8g/L, platelet ≥ 80,000/mm3
Kidney function
serum creatinine ≤ 1.5 times the normal upper limit
Liver function
ALAT/ASAT ≤ 2.5 times the normal upper limit, bilirubin ≤ 1.5 times the normal upper limit
Cardiac function
No obvious cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome, ≥ grade 2 heart disease diagnosed according to the NYHA classification criteria within 3 months prior to enrollment)
Blood routine examination: WBC < 3,000/mm3, hemoglobin < 8g/L, platelet < 80,000/mm3; Liver function: ALAT/ASAT > 2.5 times the normal upper limit, bilirubin > 1.5 times the normal upper limit; Renal function: serum creatinine > 1.5 times the normal upper limit; Obvious cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome, ≥ grade 2 heart disease diagnosed according to the NYHA classification criteria within 3 months prior to enrollment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05069857 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression > 10 CPS is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify